Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Barclays analyst Paul Kearney initiated coverage on Levi Strauss & Co. (NYSE:LEVI) with an Overweight rating and announced a price target of $24. Levi Strauss shares closed at $17.67 on Tuesday. See how other analysts view this stock.
- Truist Securities analyst Asthika Goonewardene initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and announced a price target of $35. Summit Therapeutics shares closed at $18.16 on Tuesday. See how other analysts view this stock.
- Stifel analyst Annabel Samimy initiated coverage on Altimmune, Inc. (NASDAQ:ALT) with a Buy rating and announced a price target of $18. Altimmune shares closed at $7.31 on Tuesday. See how other analysts view this stock.
- B. Riley Securities analyst Mayank Mamtani initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announced a price target of $4. Nektar Therapeutics shares closed at $1.19 on Tuesday. See how other analysts view this stock.
- JMP Securities analyst Silvan Tuerkcan initiated coverage on Context Therapeutics Inc. (NASDAQ:CNTX) with a Market Outperform rating and announced a price target of $4. Context Therapeutics shares closed at $1.09 on Tuesday. See how other analysts view this stock.
Considering buying LEVI stock? Here's what analysts think:
Read This Next:
- Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
